SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. Borggrefe, S. Giravent, G. Campbell, F. Thomsen, D. Chang, M. Franke, A. Günther, M. Heller, A. Wulff, Association of osteolytic lesions, bone mineral loss and trabecular sclerosis with prevalent vertebral fractures in patients with multiple myeloma, European Journal of Radiology, 2015, 84, 11, 2269

    CrossRef

  2. 2
    Jan Borggrefe, Sarah Giravent, Felix Thomsen, Jaime Peña, Graeme Campbell, Asmus Wulff, Andreas Günther, Martin Heller, Claus C Glüer, Association of QCT Bone Mineral Density and Bone Structure With Vertebral Fractures in Patients With Multiple Myeloma, Journal of Bone and Mineral Research, 2015, 30, 7
  3. 3
    J M Piot, M Royer, A Schmidt-Tanguy, E Hoppé, M Gardembas, T Bourrée, M Hunault, S François, F Boyer, N Ifrah, G Renier, A Chevailler, M Audran, D Chappard, H Libouban, G Mabilleau, E Legrand, B Bouvard, Factors associated with an increased risk of vertebral fracture in monoclonal gammopathies of undetermined significance, Blood Cancer Journal, 2015, 5, 8, e345

    CrossRef

  4. 4
    M. Reyskens, K. Sleurs, L. Verresen, M. Janssen, J. van den Berg, P. Geusens, Hypophosphatemic osteomalacia: an unusual clinical presentation of multiple myeloma, Osteoporosis International, 2015, 26, 7, 2039

    CrossRef

  5. 5
    Faryal Mirza, Ernesto Canalis, MANAGEMENT OF ENDOCRINE DISEASE: Secondary osteoporosis: pathophysiology and management, European Journal of Endocrinology, 2015, 173, 3, R131

    CrossRef

  6. 6
    Vasileios I. Sakellariou, Andreas F. Mavrogenis, Olga Savvidou, Franklin H. Sim, Panayiotis J. Papagelopoulos, Reconstruction of multiple myeloma lesions around the pelvis and acetabulum, European Journal of Orthopaedic Surgery & Traumatology, 2015, 25, 4, 643

    CrossRef

  7. 7
    R. Bataille, The multiple myeloma bone eco-system and its relation to oncogenesis, Morphologie, 2015, 99, 325, 31

    CrossRef

  8. 8
    J. N. Farr, W. Zhang, S. K. Kumar, R. M. Jacques, A. C. Ng, L. K. McCready, S. V. Rajkumar, M. T. Drake, Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance, Blood, 2014, 123, 5, 647

    CrossRef

  9. 9
    Evangelos Terpos, Nikolaos Kanellias, Krzysztof Giannopoulos, Biology and management of myeloma-related bone disease, Acta Haematologica Polonica, 2014, 45, 2, 107

    CrossRef

  10. 10
    Nikolaos A. Stavropoulos, Argyro Papadoyiannis, Dimitris Maltezas, Petros Stavrou, George C. Babis, Panayiotis J. Papagelopoulos, Gerasimos A. Pangalis, Marie-Christine Kyrtsonis, Biology and Treatment of Skeletal Manifestations in Multiple Myeloma, Journal of Cancer Therapy, 2014, 05, 04, 387

    CrossRef

  11. 11
    Lorenz C Hofbauer, Tilman D Rachner, Robert E Coleman, Franz Jakob, Endocrine aspects of bone metastases, The Lancet Diabetes & Endocrinology, 2014, 2, 6, 500

    CrossRef

  12. 12
    Sandrine P.G. Bours, Joop P.W. van den Bergh, Tineke A.C.M. van Geel, Piet P.M.M. Geusens, Secondary osteoporosis and metabolic bone disease in patients 50 years and older with osteoporosis or with a recent clinical fracture, Current Opinion in Rheumatology, 2014, 26, 4, 430

    CrossRef

  13. 13
    Gregory R. Emkey, Sol Epstein, Secondary osteoporosis: Pathophysiology & diagnosis, Best Practice & Research Clinical Endocrinology & Metabolism, 2014, 28, 6, 911

    CrossRef

  14. 14
    Nishant Tageja, Elisabet E. Manasanch, Neha Korde, Mary Kwok, Sham Mailankody, Manisha Bhutani, Mark Roschewski, Ola Landgren, Smoldering multiple myeloma: present position and potential promises, European Journal of Haematology, 2014, 92, 1
  15. 15
    Sakshi Sikka, Muthu K. Shanmugam, Radhamani Kannaiyan, Rohit Surana, Eun Myoung Shin, Alan Prem Kumar, Gautam Sethi, Kwang Seok Ahn, Suppression of essential pro-inflammatory signaling pathways by natural agents for the therapy of Multiple Myeloma, Phytochemistry Reviews, 2014, 13, 1, 79

    CrossRef

  16. 16
    Matthew T Drake, Unveiling Skeletal Fragility in Patients Diagnosed With MGUS: No Longer a Condition of Undetermined Significance?, Journal of Bone and Mineral Research, 2014, 29, 12
  17. 17
    Rose-Marie Javier, Découverte d’une gammapathie monoclonale au cours d’une ostéoporose, Revue du Rhumatisme Monographies, 2013, 80, 2, 116

    CrossRef

  18. 18
    Jo Caers, Marie-Christiane Vekemans, Greet Bries, Karolien Beel, Vanessa Delrieu, Anne Deweweire, Hilde Demuynck, Bernard De Prijck, Hadewijch De Samblanx, Alain Kentos, Nathalie Meuleman, Philippe Mineur, Fritz Offner, Isabelle Vande Broek, Jan Van Droogenbroeck, Ann Vande Velde, Ka Lung Wu, Michel Delforge, Rik Schots, Chantal Doyen, Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians, Annals of Medicine, 2013, 45, 5-6, 413

    CrossRef

  19. 19
    Patrizia Tosi, Diagnosis and Treatment of Bone Disease in Multiple Myeloma: Spotlight on Spinal Involvement, Scientifica, 2013, 2013, 1

    CrossRef

  20. 20
    Matthew T. Drake, Osteoporosis and Cancer, Current Osteoporosis Reports, 2013, 11, 3, 163

    CrossRef

  21. 21
    Rebecca Silbermann, G. David Roodman, Osteoporosis, 2013,

    CrossRef

  22. 22
    Martina Kleber, Josefina Udi, Barbara Metzke, Evangelos Terpos, G. David Roodmann, Gareth Morgan, Angela Dispenzieri, Hermann Einsele, Ralph Wäsch, Monika Engelhardt, Challenging the current approaches to multiple myeloma- and other cancer-related bone diseases: from bisphosphonates to targeted therapy, Leukemia & Lymphoma, 2012, 53, 6, 1057

    CrossRef

  23. 23
    Terry Golombick, Terrence H. Diamond, Arumugam Manoharan, Rajeev Ramakrishna, Monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, and curcumin: A randomized, double-blind placebo-controlled cross-over 4g study and an open-label 8g extension study, American Journal of Hematology, 2012, 87, 5
  24. 24
    James R. Berenson, Ori Yellin, Albert Quiery, James Brady, Ravi Patel, Siu-Fun Wong, Donald Colbourn, Donald Gravenor, Natasha Tiffany, H.K. Shamasunder, Benjamin Waterman, Kathryn Melamed, Eric Wirtschafter, A Retrospective Study to Evaluate the Work-up and Follow-up of Patients With Monoclonal Gammopathy of Undetermined Significance, Clinical Lymphoma Myeloma and Leukemia, 2011, 11, 4, 336

    CrossRef

  25. 25
    Sigurdur Y Kristinsson, Alex R Minter, Neha Korde, Esther Tan, Ola Landgren, Bone disease in multiple myeloma and precursor disease: novel diagnostic approaches and implications on clinical management, Expert Review of Molecular Diagnostics, 2011, 11, 6, 593

    CrossRef

  26. 26
    A. C. Ng, S. Khosla, N. Charatcharoenwitthaya, S. K. Kumar, S. J. Achenbach, M. F. Holets, L. K. McCready, L. J. Melton, R. A. Kyle, S. V. Rajkumar, M. T. Drake, Bone microstructural changes revealed by high-resolution peripheral quantitative computed tomography imaging and elevated DKK1 and MIP-1  levels in patients with MGUS, Blood, 2011, 118, 25, 6529

    CrossRef

  27. 27
    Evangelos Terpos, Meletios A. Dimopoulos, James Berenson, Established role of bisphosphonate therapy for prevention of skeletal complications from myeloma bone disease, Critical Reviews in Oncology/Hematology, 2011, 77, S13

    CrossRef

  28. 28
    Sandra I. Rome, Bonnie S. Jenkins, Kathryn E. Lilleby, Mobility and Safety in the Multiple Myeloma Survivor, Clinical Journal of Oncology Nursing, 2011, 15, 0, 41

    CrossRef

  29. 29
    Ola Landgren, Multiple Myeloma Precursor Disease: Current Clinical Dilemma and Future Opportunities, Seminars in Hematology, 2011, 48, 1, 1

    CrossRef

  30. 30
    Brendan M Weiss, W Michael Kuehl, Advances in understanding monoclonal gammopathy of undetermined significance as a precursor of multiple myeloma, Expert Review of Hematology, 2010, 3, 2, 165

    CrossRef

  31. 31
    L. C. Hofbauer, C. Hamann, P. R. Ebeling, Approach to the patient with secondary osteoporosis, European Journal of Endocrinology, 2010, 162, 6, 1009

    CrossRef

  32. 32
    Maurizio Zangari, Fenghuang Zhan, Guido Tricot, Bone and paraproteinemias, Current Opinion in Supportive and Palliative Care, 2010, 4, 3, 195

    CrossRef

  33. 33
    Béatrice Bouvard, Mathieu Royer, Daniel Chappard, Maurice Audran, Emmanuel Hoppé, Erick Legrand, Gammapathie monoclonale de signification indéterminée, myélome multiple et ostéoporose, Revue du Rhumatisme, 2010, 77, 2, 144

    CrossRef

  34. 34
    S. Y. Kristinsson, M. Tang, R. M. Pfeiffer, M. Bjorkholm, C. Blimark, U.-H. Mellqvist, A. Wahlin, I. Turesson, O. Landgren, Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study, Blood, 2010, 116, 15, 2651

    CrossRef

  35. 35
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, Current Hematologic Malignancy Reports, 2010, 5, 2, 62

    CrossRef

  36. 36
    O. Landgren, Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: New Insights into Pathophysiology and Epidemiology, Hematology, 2010, 2010, 1, 295

    CrossRef

  37. 37
    Béatrice Bouvard, Mathieu Royer, Daniel Chappard, Maurice Audran, Emmanuel Hoppé, Erick Legrand, Monoclonal gammopathy of undetermined significance, multiple myeloma, and osteoporosis, Joint Bone Spine, 2010, 77, 2, 120

    CrossRef

  38. You have free access to this content38
    James R. Berenson, Kenneth C. Anderson, Robert A. Audell, Ralph V. Boccia, Morton Coleman, Meletios A. Dimopoulos, Matthew T. Drake, Rafael Fonseca, Jean-Luc Harousseau, Douglas Joshua, Sagar Lonial, Ruben Niesvizky, Antonio Palumbo, G. David Roodman, Jesus F. San-Miguel, Seema Singhal, Donna M. Weber, Maurizio Zangari, Eric Wirtschafter, Ori Yellin, Robert A. Kyle, Monoclonal gammopathy of undetermined significance: a consensus statement, British Journal of Haematology, 2010, 150, 1
  39. 39
    Adam J. Waxman, Michael Kuehl, Arun Balakumaran, Brendan Weiss, Ola Landgren, Smoldering (Asymptomatic) Multiple Myeloma: Revisiting the Clinical Dilemma and Looking Into the Future, Clinical Lymphoma Myeloma and Leukemia, 2010, 10, 4, 248

    CrossRef

  40. 40
    Fergus E. McKiernan, Technetium-99m–Methyl Diphosphonate Bone Scintigraphy May Be Helpful in Preoperative Planning for Vertebroplasty in Multiple Myeloma: Two Cases, Journal of Vascular and Interventional Radiology, 2010, 21, 9, 1462

    CrossRef

  41. 41
    S. Lonial, The White House crusade against ... MGUS?, Blood, 2010, 116, 7, 1020

    CrossRef

  42. 42
    James R. Berenson, Therapeutic Options in the Management of Myeloma Bone Disease, Seminars in Oncology, 2010, 37, S20

    CrossRef

  43. 43
    John P. Bida, Robert A. Kyle, Terry M. Therneau, L. Joseph Melton, Matthew F. Plevak, Dirk R. Larson, Angela Dispenzieri, Jerry A. Katzmann, S. Vincent Rajkumar, Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients, Mayo Clinic Proceedings, 2009, 84, 8, 685

    CrossRef

  44. 44
    James R. Berenson, Ori Yellin, Monoclonal Gammopathy of Undetermined Significance: Why Identification of These Patients and Assessment of Their Skeletons Is Important, Clinical Lymphoma and Myeloma, 2009, 9, 4, 311

    CrossRef

  45. 45
    O. Landgren, R. A. Kyle, V. Rajkumar, Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions, Blood, 2009, 114, 11, 2356

    CrossRef

  46. 46
    Sumit Madan, Philip R. Greipp, The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS), Blood Reviews, 2009, 23, 6, 257

    CrossRef

  47. You have free access to this content47
    Jenny Bird, Judith Behrens, Jan Westin, Ingemar Turesson, Mark Drayson, Robert Beetham, Shirley D’Sa, Richard Soutar, Anders Waage, Nina Gulbrandsen, Henrik Gregersen, Eric Low, UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS), British Journal of Haematology, 2009, 147, 1
  48. 48
    Omer Dizdar, Mustafa Erman, Mustafa Cankurtaran, Meltem Halil, Zekeriya Ulger, Burcu Balam Yavuz, Servet Ariogul, Aslı Pınar, Hakan Harputluoglu, Ayse Kars, İsmail Çelik, Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance, Annals of Hematology, 2008, 87, 1, 57

    CrossRef

  49. You have free access to this content49
    Allison P. Armstrong, Robert E. Miller, Jon C. Jones, Jian Zhang, Evan T. Keller, William C. Dougall, RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes, The Prostate, 2008, 68, 1
  50. 50
    B. J. Edwards, C. B. Langman, A. D. Bunta, M. Vicuna, M. Favus, Secondary contributors to bone loss in osteoporosis related hip fractures, Osteoporosis International, 2008, 19, 7, 991

    CrossRef

  51. 51
    Fred Saad, Richard Markus, Carsten Goessl, Targeting the receptor activator of nuclear factor-κB (RANK) ligand in prostate cancer bone metastases, BJU International, 2008, 101, 9
  52. 52
    Jessica Pepe, Maria Teresa Petrucci, Maria Lucia Mascia, Sara Piemonte, Valeria Fassino, Elisabetta Romagnoli, Salvatore Minisola, The Effects of Alendronate Treatment in Osteoporotic Patients Affected by Monoclonal Gammopathy of Undetermined Significance, Calcified Tissue International, 2008, 82, 6, 418

    CrossRef

  53. 53
    AILLEEN HERAS-HERZIG, WENDE M. KOZLOW, SUE A. BROWN, THERESA A. GUISE, Osteoporosis, 2008,

    CrossRef

  54. 54
    Monoclonal Gammopathy of Undetermined Significance, New England Journal of Medicine, 2007, 356, 21, 2223

    CrossRef

  55. 55
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, Hematology/Oncology Clinics of North America, 2007, 21, 6, 1093

    CrossRef

  56. 56
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression, British Journal of Haematology, 2007, 139, 5
  57. 57
    Inge Stewart, Claire Roddie, Anthony Gill, Adele Clarkson, Michiko Mirams, Luke Coyle, Christopher Ward, Philip Clifton-Bligh, Bruce G. Robinson, Rebecca S. Mason, Roderick J. Clifton-Bligh, Elevated serum FGF23 concentrations in plasma cell dyscrasias, Bone, 2006, 39, 2, 369

    CrossRef

  58. 58
    Henrik Gregersen, Paw Jensen, Mette Gislum, Birgit Jørgensen, Henrik Toft Sørensen, Mette Nørgaard, Fracture risk in patients with monoclonal gammopathy of undetermined significance, British Journal of Haematology, 2006, 135, 1
  59. 59
    Jessica Pepe, Maria Teresa Petrucci, Italo Nofroni, Valeria Fassino, Daniele Diacinti, Elisabetta Romagnoli, Salvatore Minisola, Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of undetermined significance, British Journal of Haematology, 2006, 134, 5
  60. 60
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal gammopathy of undetermined significance, British Journal of Haematology, 2006, 134, 6
  61. 61
    Howard S. Yeh, James R. Berenson, Myeloma bone disease and treatment options, European Journal of Cancer, 2006, 42, 11, 1554

    CrossRef

  62. 62
    Pierrick GJ Fournier, John M Chirgwin, Theresa A Guise, New insights into the role of T cells in the vicious cycle of bone metastases, Current Opinion in Rheumatology, 2006, 18, 4, 396

    CrossRef

  63. 63
    Marianna C. Politou, Deborah J. Heath, Amin Rahemtulla, Richard Szydlo, Athanasios Anagnostopoulos, Meletios A. Dimopoulos, Peter I. Croucher, Evangelos Terpos, Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation, International Journal of Cancer, 2006, 119, 7
  64. 64
    L Joseph Melton, Robert A Kyle, Sara J Achenbach, Ann L Oberg, S Vincent Rajkumar, Fracture Risk With Multiple Myeloma: A Population-Based Study, Journal of Bone and Mineral Research, 2005, 20, 3
  65. 65
    Robert A. Kyle, S. Vincent Rajkumar, Monoclonal Gammopathy of Undetermined Significance, Clinical Lymphoma and Myeloma, 2005, 6, 2, 102

    CrossRef

  66. 66
    James R. Berenson, Myeloma bone disease, Best Practice & Research Clinical Haematology, 2005, 18, 4, 653

    CrossRef

  67. 67
    Sumit Madan, Philip R. Greipp, Plasma Cell Disorders,
  68. 68
    Peter R. Ebeling, Secondary Causes of Osteoporosis: Bone Diseases,